


A VALIDATED PERSONALIZED PROGNOSTIC TOOL

CDPATH™ is a validated prognostic tool that uses a blood test* to evaluate an adult Crohn's disease (CD) patient's potential risk for developing serious complications† within 3 years and can help facilitate shared decision-making.^{1,2}

Healthcare professionals should not rely primarily on the risk predictions from CDPATH to make a clinical diagnosis or treatment decision regarding an individual patient.

CDPATH development and validation


① Defining the Model Through a Calibration Cohort in an Independent Clinical Study¹



② Establishing Clinical Relevance Through a Validation Cohort in an Independent Clinical Study^{1,2}



③ Developing and Validating the Laboratory Developed Test(LDT)²



*The CDPATH risk assessment tool was developed and validated by Prometheus Laboratories Inc., a partner of Takeda. Test results are provided via Prometheus Laboratories Inc. to physicians.²

ASCA=anti-Saccharomyces cerevisiae antibodies; CBir1=anti-flagellin; IgA=immunoglobulin A; IgG=immunoglobulin G; NOD2=nucleotide-binding oligomerization domain 2; pANCA=perinuclear anti-neutrophil antibody; SNP=single nucleotide polymorphism.

1. Siegel CA, Horton H, Siegel LS, et al. *Aliment Pharmacol Ther.* 2016;43(2):262-271.

2. Data on file. Takeda Pharmaceuticals.